Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to Castle Biosciences Fourth Quarter and Full Year 2025 Conference Call. As a reminder, today's call is being recorded.
Castle Biosciences Inc (CSTL)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Portolan Capital Management George Mccabe | 1,729,463 | $67,276,111 | +15% | 3.6% |
| 2. | AIGH Investment Partners Orin Hirschman | 624,719 | $24,301,569 | -12% | 5.88% |
| 3. | Renaissance Technologies Jim Simons | 493,100 | $19,181,590 | -13% | 0.03% |
| 4. | Citadel Investment Group Ken Griffin | 366,356 | $14,251,249 | +47% | 0% |
| 5. | Millennium Management Israel Englander | 308,914 | $12,016,755 | -47% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.27 | 2,500 | $43,175.00 | 9,065 | 2023-06-05 | Filing | |
| $11.23 | 2,300 | $25,829.00 | 6,565 | 2023-06-05 | Filing | |
| $21.50 | 1,162 | $24,983.00 | 2,968 | 2022-11-29 | Filing | |
| $18.77 | 220 | $4,129.40 | 1,806 | 2022-05-12 | Filing | |
| $18.76 | 1,100 | $20,636.00 | 1,586 | 2022-05-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.39 | 650 | $16,503.50 | 21,479 | 2026-03-18 | Filing | |
| $25.93 | 18,650 | $483,594.50 | 22,129 | 2026-03-17 | Filing | |
| $26.68 | 126 | $3,361.68 | 40,779 | 2026-03-16 | Filing | |
| $25.96 | 17,449 | $453,045.84 | 40,905 | 2026-03-16 | Filing | |
| $25.45 | 13,204 | $336,002.19 | 58,354 | 2026-03-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,105,246 | $120,794,069 | 0% | |
| 2. | 2,199,829 | $85,573,349 | 0% | |
| 3. | 2,115,237 | $82,282,719 | 0.82% | |
| 4. | 1,807,644 | $70,317,352 | 0.04% | |
| 5. | 1,143,799 | $44,494,673 | 0.01% |
News See All
Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to Castle Biosciences' Third Quarter 2025 Conference Call. As a reminder, today's call is being recorded.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2025 Earnings Call Transcript
Operator: Good afternoon all, and thank you for joining us for the Castle Biosciences' Q2 2025 Earnings Call. As a reminder, this call is being recorded.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2025 Earnings Call Transcript
Operator: Good afternoon and welcome to Castle Biosciences First Quarter 2025 Conference Call. As a reminder, today's call is being recorded.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to Castle Biosciences Fourth Quarter and Full Year 2024 Conference Call. As a reminder, today's call is being recorded.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to Castle Biosciences Third Quarter 2024 Conference Call. As a reminder, today's call is being recorded.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to Castle Biosciences Second Quarter 2024 Conference Call. As a remainder, today's call is being recorded.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to Castle Biosciences First Quarter 2024 Conference Call. As a remainder, today's call is being recorded.
What Makes Castle Bioscience (CSTL) a Prospective Investment?
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds released “The RiverPark/Next Century Growth Fund” Q4 2023 investor letter in partnership with Next...
Hedge Fund Resource Center